To the full analysis
Phibro Animal Health stock: growth
PAHCPhibro Animal Health reported $1.52B in revenue for fiscal 2026, up 17.1% on the prior year, up 12.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.6%
per year from 2007 to 2026, per share 6.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 12.7% | 7.3% | 6.6% |
| Revenue per share | 12.7% | 6.9% | 6.3% |
| Earnings | 12.9% | 1.9% | no data |
| Earnings per share | 12.9% | 1.5% | no data |
| Free cash flow | −12.3% | 27.5% | no data |
| Free cash flow per share | −12.3% | 27.1% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $453M | −$6.7M | −$15.35M |
| 2008 | $511.4M | $2.2M | $0 |
| 2009 | $537.1M | −$8.3M | $0 |
| 2010 | $594.2M | $42.1M | $0 |
| 2011 | $618.33M | −$12.92M | −$26.32M |
| 2012 | $654.1M | $6.98M | $17.16M |
| 2013 | $653.15M | $24.89M | −$19.53M |
| 2014 | $691.9M | −$3.1M | −$20.56M |
| 2015 | $748.59M | $60.28M | $48.65M |
| 2016 | $751.5M | $82.7M | $866K |
| 2017 | $764.3M | $64.6M | $77.5M |
| 2018 | $820M | $64.9M | $51.46M |
| 2019 | $828M | $54.7M | $17.28M |
| 2020 | $800.35M | $33.55M | $25.3M |
| 2021 | $833.35M | $54.39M | $18.99M |
| 2022 | $942.26M | $49.18M | −$5.4M |
| 2023 | $977.89M | $32.61M | −$38.48M |
| 2024 | $1.02B | $2.42M | $46.36M |
| 2025 | $1.3B | $48.26M | $41.83M |
| 2026 | $1.52B | $99.72M | $9.87M |
Revenue by region
Where Phibro Animal Health Corporation generates its revenue.
- United States58%
- Latin America and Canada22%
- EMEA12%
- Asia Pacific7%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|
| United States | $561.8M | $578.77M | $584.76M | $739.92M | $877.13M | 57.8% |
| Latin America and Canada | $191.05M | $219.85M | $247.71M | $298.65M | $340.67M | 22.4% |
| EMEA | $122.48M | $117.82M | $121.98M | $160.23M | $187.94M | 12.4% |
| Asia Pacific | $66.93M | $61.46M | $63.23M | $97.42M | $112.36M | 7.4% |
| Total revenue | $942.26M | $977.89M | $1.02B | $1.3B | $1.52B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.